HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission.
Abstract: The majority of the M184 V mutations were observed in parturient women on first line regimen (n = 23; 82.1%).
Abstract: The predominant DRMs were K103 N (n = 43; 74.1%), M184 V (n = 28; 48.3%) and K65R (n = 11; 19%).
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
PMID: 31257432
2019
The Journal of antimicrobial chemotherapy
Abstract: The most prevalent mutations were M184V/I (53.6%) for NRTIs and K103N (39.2%) for NNRTIs.
Result: The most prevalent NRTI mutations were M184V/I (53.6%), K65R (17.5%) and thymidine analogue mutations (TAMs) were present in 21.6% of VF cases.
Discussion: The most prevalent NRTI mutations, M184V/I, are selected by and cause high-level resistance to cytosine analogue NRTIs, lamivudine and emtricitabine.
Discussion: The rampant prevalence of the M184V/I and K65R mutations may not warrant the discontinuation of
A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
Abstract: HIV resistance testing was available for 78% (28/38), of whom 82.1% (23/28) had at least one major drug resistance mutation (DRM), most frequently M184V (70%, 16/23) and K103N (65%, 15/23).
Introduction: The lamivudine (3TC, an NRTI drug) mutation M184V and the efavirenz (EFV) and nevirapine (NVP) (two NNRTI drugs) mutations K103N and 181C are frequently observed in cases of virological failure.
Table: M184V
Discussion: Furthermore, consistent with findings from Rwanda, the most predominant mutations observed in this study were M184V for NRTI and K103N for NNRTIs.
Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.
Abstract: In both scenarios, we find comparably high prevalence (~80%) of acquired NNRTI-associated, M184V and K65R mutations.
Abstract: METHODS: We constructed a stochastic individual-based model and simulated scenarios of ART implementation, either CD4-based (threshold < 500 cells/mL) or Fast-track (81% coverage by 2020), with consideration of major drug-associated mutations (M184V, K65R and non-nucleoside reverse transcriptase inhibitor (NNRTI)).
Result: Irrespective of the scenario, the prevalence of the NNRTI-associated (class), M184V and K65R (signature) mutatio
Table: M184V
HIV-1 Drug Resistance Mutations among Antiretroviral Drug-Experienced Patients in the South of Iran.
Abstract: M184V (40.9%) and K103N (25%), respectively related to NRTI and nonnucleoside reverse-transcriptase inhibitor (NNRTI), were the mutations with the highest frequencies.
Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
PMID: 31422059
2019
Journal of microbiology, immunology, and infection
Abstract: Nineteen patients (3 [3.2%] in dual-therapy and 16 [7.6%] in triple-therapy group) developed virologic failure, with none having emergent M184V resistance-associated mutation.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Abstract: At week 48, 98% (561/570) of all BIC/FTC/TAF-treated participants versus 98% (213/217) with pre-existing resistance and 96% (52/54) with archived M184V/I had HIV-1 RNA <50 copies/mL.
Abstract: CONCLUSIONS: Pre-existing resistance substitutions, notably M184V/I, were unexpectedly common among suppressed participants who switched to BIC/FTC/TAF.
Abstract: High rates of virological suppression were maintained in the overall study population and in those with pre-existing resistance, including M184V/I, for up to 48 weeks of BIC/FTC/TAF treatment with no resistance development.
Abstract: Pre-switch NRTI resistance was detected in 16% (89/543) of BIC/FTC/TAF-treated participants, with M184V or M184I detected by proviral genotyping in 10% (54/
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
HIV mutation literature information.
PMID: 
2019
Journal of clinical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT